Principal Street Partners’s Adicet Bio ACET Stock Holding History

Principal Street Partners’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,345	Closed	-$1.33M	–	195
2019 Q3	$1.33M	Buy	+1,345	New	+$1.5M	0.33%	55

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Street Partners's ACET Position: Q4 2019 in Review

Principal Street Partners sold out of Adicet Bio (ACET) in Q4 2019, closing a stake of 1,345 shares — an estimated $1.33M sold.

Principal Street Partners first reported a position in ACET in Q3 2019 and held it in 1 quarter. The position peaked at $1.33M in Q3 2019. 54 funds tracked by Wall St. Rank hold ACET as of Q4 2019.

Principal Street Partners reported no remaining Adicet Bio position as of Q4 2019 after selling out during the quarter.
Principal Street Partners sold 1,345 Adicet Bio shares in Q4 2019, an estimated $1.33M.
Principal Street Partners first reported a position in Adicet Bio in Q3 2019 and held it in 1 quarter.
Principal Street Partners's Adicet Bio position peaked at $1.33M in Q3 2019.
54 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2019.

Based on Principal Street Partners's 13F filing for Q4 2019, filed 4 Mar 2020.